Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) services with the launch of the ezBVA lab service in three new facilities, anticipating sustained accelerated sales growth for the remainder of the year [1][3] Company Developments - Recent sales achievements include the adoption of Daxor's ezBVA Lab service by a leading full-service medical center in Georgia, a purchase by a hospital in North Carolina that is part of the largest non-profit health system, and implementation by a top-rated hospital in Central Florida [2] - The ezBVA lab service is a CLIA certified facility that provides next-day blood volume analysis results, enhancing patient care while managing healthcare expenses [3] Technology and Impact - Daxor's BVA-100® is the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition, with over 65,000 tests performed across leading U.S. hospital centers [4] - The technology has shown significant benefits in reducing mortality and readmissions in heart failure and critical care patients, indicating its critical role in fluid management [4]
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide